Contains fulltext :
                  203569.pdf (publisher's version ) (Open Access

Bizino, M.B.

Eyk, Huub J. van

Jazet, Ingrid M.

Lamb, H.J.

Paiman, Elisabeth H.M.

Smit, J.W.A.

Westenberg, J.J.

Following publication of the original article [1], the authors reported an error in Fig. 3. The bars in the upper right panel that represent heart rate in placebo treated patients is not correct

Jazet, I.M.

Westenberg, J.J.M.

Eyk, H.J. van

Paiman, E.H.M.

NARCIS 

Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: randomized placebo-controlled trial (vol 18, pg 55, 2019)

BackgroundLiraglutide is an antidiabetic agent with cardioprotective effect. The purpose of this study is to test efficacy of liraglutide to improve diabetic cardiomyopathy in patients with diabetes mellitus type 2 (DM2) without cardiovascular disease.MethodsPatients with DM2 were randomly assigned to receive liraglutide 1.8mg/day or placebo in this double-blind trial of 26weeks. Primary outcome measures were LV diastolic function (early (E) and late (A) transmitral peak flow rate, E/A ratio, early deceleration peak (Edec), early peak mitral annular septal tissue velocity (Ea) and estimated LV filling pressure (E/Ea), and systolic function (stroke volume, ejection fraction, cardiac output, cardiac index and peak ejection rate) assessed with CMR. Intention-to-treat analysis of between-group differences was performed using ANCOVA. Mean estimated treatment differences (95% confidence intervals) are reported.Results23 patients were randomized to liraglutide and 26 to placebo. As compared with placebo, liraglutide significantly reduced E (-56mL/s (-91 to -21)), E/A ratio (-0.17 (-0.27 to -0.06)), Edec (-0.9mL/s(2)*10(-3) (-1.3 to -0.2)) and E/Ea (-1.8 (-3.0 to -0.6)), without affecting A (3mL/s (-35 to 41)) and Ea (0.4cm/s (-0.9 to 1.4)). Liraglutide reduced stroke volume (-9mL (-16 to -2)) and ejection fraction (-3% (-6 to -0.1)), but did not change cardiac output (-0.4L/min (-0.9 to 0.2)), cardiac index (-0.1L/min/m(2) (-0.4 to 0.1)) and peak ejection rate (-46mL/s (-95 to 3)).ConclusionsLiraglutide reduced early LV diastolic filling and LV filling pressure, thereby unloading the left ventricle. LV systolic function reduced and remained within normal range. Future studies are needed to investigate if liraglutide-induced left ventricular unloading slows progression of diabetic cardiomyopathy into symptomatic stages.Diabetes mellitus: pathophysiological changes and therap

Leiden University Scholary Publications

Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: randomized placebo-controlled trial

Following publication of the original article [1], the authors reported an error in Fig. 3. The bars in the upper right panel that represent heart rate in placebo treated patients is not correct.Diabetes mellitus: pathophysiological changes and therap

Radboud Repository

https://repository.ubn.ru.nl/bitstream/handle/2066/203569/203569.pdf

Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: randomized placebo-controlled trial

Abstract

Similar works

Full text

Available Versions

NARCIS

Leiden University Scholary Publications

Leiden University Scholary Publications

NARCIS

Radboud Repository